Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this controlled clinical trial publication.

Although loss of BMD appears to be greatest within the first year of starting ADT, there are few long-term studies of change in BMD, and risk factors for bone loss are not well-characterized.

Who Took Part

The study group was 80 men.

PubMed indexes the participants as middle-aged adults, older adults and people over 80, men only.

Men aged 50+ with nonmetastatic prostate cancer starting continuous ADT were enrolled in a prospective longitudinal study.

Matched controls were men with prostate cancer not receiving ADT.

How the Study Was Run

Multivariable regression analysis examined predictors of BMD loss.

What Was Measured

Although loss of BMD appears to be greatest within the first year of starting ADT, there are few long-term studies of change in BMD, and risk factors for bone loss are not well-characterized.

Topics PubMed links to this paper include Androgen Antagonists, Bone Density, Bone Density Conservation Agents, Calcium, Femur Neck, Hip Joint and Lumbar Vertebrae.

What This Means in Plain Language

This is a controlled clinical trial of Vitamin D, K2, Magnesium and Zinc in 80 men.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.